“Genome Editing of Immune Cells” – New Lonza Virtual Event

On September 20, 2022, Lonza will host a free virtual workshop on using genome editing technologies for cell and gene therapies and drug discovery. The 3-hour workshop brings together renowned genome editing experts from across industry and academia and comprises four interactive speaker sessions and a concluding panel discussion. The event is a chance for researchers to engage directly with leading voices in the field, keep up to date with the latest CRISPR research and application, and discover tips and tricks for optimized CRISPR editing and screening.

Interest in cell and gene therapies is growing at pace, driven by their potential to address the rarest and most complex human diseases. CRISPR technology has revolutionized this sector, offering a simple, precise, and accurate gene-editing tool to expedite and scale discovery and development. Similarly, CRISPR is opening opportunities for optimized basic research and drug discovery in a range of other therapeutic areas. Gathering a community of researchers that are at the forefront of the CRISPR revolution can help foster innovation, ultimately enabling more fruitful research and better patient treatments.

The event will bring together four internationally recognized experts in the field of genome editing, holding positions in respected global institutions such as the Berlin Center for Advanced Therapies and Stanford University. The speakers have made significant contributions to the field, including through creating new methods for high-throughput genetic engineering of primary human immune cells, and enhancing the intrinsic antitumor capacity of natural killer cells. During 25-minute speaker sessions, the experts will discuss:

  • Generation of tumor-specific T cells using virus-free CRISPR gene editing
  • Genome editing of natural killer cells
  • Best practices for setting up CRISPR screens, including how to find optimal conditions to set up arrayed CRISPR screenings
  • Phenotypic CRISPR screening in human iPSC-derived macrophages as a platform for drug discovery